The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Mashin V.V.

Ulyanovsk State University

Belova L.A.

Ulyanovsk State University

Kotova E.Y.

Ulyanovsk State University

Dolgova D.R.

Ulyanovsk State University

Statenina A.P.

Ulyanovsk State University

Belyaeva Y.K.

Ulyanovsk State University

Dergacheva A.S.

Ulyanovsk State University

Israfilova R.R.

Ulyanovsk State University

Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study)

Authors:

Mashin V.V., Belova L.A., Kotova E.Y., Dolgova D.R., Statenina A.P., Belyaeva Y.K., Dergacheva A.S., Israfilova R.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(12): 34‑41

DOI: 10.17116/jnevro202312312134

Read: 2254 times

Download PDF (RU)
Contact the author
Table of contents

RESULTS OF A MULTICENTER OBSERVATIONAL PROGRAM TO EVALUATE THE EFFECTIVENESS OF COMPLEX THERAPY OF PATIENTS WITH CHRONIC CEREBROVASCULAR PATHOLOGY WITH COGNITIVE IMPAIRMENT WITH CORTEXIN AND NEUROMEXOL (CORNELIA STUDY)
RESULTS OF A MULTICENTER OBSERVATIONAL PROGRAM TO EVALUATE THE EFFECTIVENESS OF COMPLEX THERAPY OF PATIENTS WITH CHRONIC CEREBROVASCULAR PATHOLOGY WITH COGNITIVE IMPAIRMENT WITH CORTEXIN AND NEUROMEXOL (CORNELIA STUDY)

To cite this article:

Mashin VV, Belova LA, Kotova EY, et al. . Results of a multicenter observational program to evaluate the effectiveness of complex therapy of patients with chronic cerebrovascular pathology with cognitive impairment with Cortexin and Neuromexol (CORNELia study). S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(12):34‑41. (In Russ.)
https://doi.org/10.17116/jnevro202312312134

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
The role of gene­tic poly­morphisms in folate meta­bolism genes in the mani­festation of migraine in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):47-52
Functional state of the kidneys in patients with various types of cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):105-111
Comparative study of cognitive impairment in subgroups of bipo­lar affe­ctive diso­rder types I and II, occu­rring with and without psychotic symptoms. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):7-11
Rela­tionship between stroke-associated pneumonia and long-term outcomes of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):57-61
Pote­ntial of animal-derived neuropeptides in complex therapy of diabetic neuropathy in patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):83-87
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
Differential diagnosis of Alzheimer’s disease and vascular cognitive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):26-35
Prevalence of cere­brovascular diseases risk factors acco­rding to the cohort survey data in Bishkek, Kyrgyz Repu­blic. Russian Journal of Preventive Medi­cine. 2025;(3):34-39
Study of the levo­carnitine effi­cacy for the treatment of mode­rate cognitive impairment in patients with hype­rtension. Russian Journal of Preventive Medi­cine. 2025;(4):45-50
Abstract:

OBJECTIVE

To evaluate the effectiveness of complex therapy with Cortexin and Neuromexol in patients with chronic cerebral ischemia (CCI) and cognitive impairment (CI).

MATERIAL AND METHODS

We examined 801 patients with CCI on the background of arterial hypertension and atherosclerosis with confirmed CI: 329 (41.1%) men and 472 (58.9%) women aged 30 to 80 years (mean age 64±10 years), who were examined. Cortexin and Neuromexol. Examination — Mini-Mental State Examination (MMSE) scale, hour-long drawing test (HDT) and severity of depressive states (Brief Geriatric Depression Scale, Mini Geriatric Depression Scal, MGDS). In 30 patients receiving Cortexin and Neuromexol (main group, MG) and 30 patients in the comparison group (CG), biomarkers of ischemic brain damage (NSE, antibodies to NR2, VEGFA) were determined. The examination was carried out before the start of treatment and after 30 days.

RESULTS

During therapy with Cortexin and Neuromexol, characteristic signs of a decrease in the severity of CI were noted (p<0.05). A positive correlation was revealed between the performance indicators of the MMSE and TFC tests, both before and after treatment (r=0.5 and r=0.6, respectively; p<0.05). A positive effect of therapy on the emotional background of patients was noted, in particular, a decrease in the severity of depressive symptoms on the MGDS scale. During therapy, a 2-fold decrease in the NSE level (p<0.05) was detected in the MG, which indicates a decrease in the structural and functional parameters of biomembrane neurons in the brain. The concentration of antibodies to NR2 decreased compared to the baseline level in both groups (p<0.05), and VEGFA decreased only in the MG (p<0.05).

CONCLUSION

The results of the study allow us to recommend the complex prescription of Cortexin 10 mg/day for 10 days and Neuromexol tablets 125 mg (375-750 mg/day) for 30 days for chronic CVD. Complex therapy with Cortexin and Neuromexol is effective and safe in patients with CCI and CI

Keywords:

dyscirculatory encephalopathy
cerebrovascular diseases
cognitive impairment
Cortexin
Neuromexol

Authors:

Mashin V.V.

Ulyanovsk State University

Belova L.A.

Ulyanovsk State University

Kotova E.Y.

Ulyanovsk State University

Dolgova D.R.

Ulyanovsk State University

Statenina A.P.

Ulyanovsk State University

Belyaeva Y.K.

Ulyanovsk State University

Dergacheva A.S.

Ulyanovsk State University

Israfilova R.R.

Ulyanovsk State University

Received:

13.10.2023

Accepted:

11.11.2023

Close metadata

References:

  1. Bogolepova AN. Cognitive impairment in patients with cerebrovascular disease. Treatment of nervous diseases. 2011;3(8):16-21. (In Russ.).
  2. Gusev EI, Bogolepova AN. Cognitive impairment in cerebrovascular diseases. M.: MEDpress-inform Publ.; 2013. (In Russ.).
  3. Trojano C, Anderson C, Chapman N, et al. Cognitive Impairment: a key feature of congestive heart failure in the elderly. J Neurol. 2003;250:1456-1463.
  4. Modgero PL, Ferrandez J. Depression in patients with mild cognitive impairment increases the risk of developing dementia of Alzheimer type. A prospective cohort study. Arc Neurol. 2004;61:1290-1293.
  5. Reis C, Akyol O, Ho WM, et al. Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. Biomed Res Int. 2017;2017:4863079.
  6. Ponomarev GV, Voznyuk IA, Izumi MA, Skoromets AA. Glutamate biomarkers in the complex diagnosis of acute and chronic cerebral ischemia Annals of clinical and experimental neurology. 2020;14(4):15-22. (In Russ.). https://doi.org/10.25692/ACEN.2020.4.2
  7. Khunteev GA, Zavolokov IG, Cherkas YuV, Dambinova SA. The practical significance of determining the level of antibodies to the NMDA type of glutamate receptors in the diagnosis of cerebral circulatory disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2001;101(11):44-47. (In Russ.).
  8. Granstrem OK, Dambinova SA, Dyakonov MM, at al. Dynamics of biomarkers of brain ischemia in dyscirculatory encephalopathy during treatment with Cortexin. Medline Express. 2009;4-5(203):29-33. (In Russ.).
  9. Grubb NR, Simpson C, Sherwood RA, et al. Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. Heart. 2007;93:1268-1273. https://doi.org/10.1136/hrt.2006.091314
  10. Oertel M, Schumacher U, McArthur DL, et al. S-100B and NSE: markers of initial impact of subarachnoid haemorrhage and their relation to vasospasm and outcome. J Clin Neurosci. 2006;13:834-840.  https://doi.org/10.1016/j.jocn.2005.11.030
  11. Celtik C, Acunaş B, Oner N, Pala O. Neuron-specific enolase as a marker of the severity and outcome of hypoxic ischemic encephalopathy. Brain Dev. 2004;26:398-402.  https://doi.org/10.1016/j.braindev.2003.12.007
  12. Koroleva ES, Brazovskaya NG, Levchuk LA, et al. Assessment of the levels of neuron-specific enolase and brain-derived neurotrophic factor at the stages of rehabilitation in the acute and early recovery periods of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(8 issue 2):30-36. (In Russ.). https://doi.org/10.17116/jnevro202012008230
  13. Topuzova MP, Alekseeva TM, Panina EB, et al. Possibility of using neuron-specific enolase as a biomarker in the acute period of stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(8 issue 2):53-62. (In Russ.). https://doi.org/10.17116/jnevro201911908253
  14. Maikotova AM. Cerebrovascular dysfunction in patients with arterial hypertension. Neurosurgery and neurology of Kazakhstan. 2013;33(4):11-14. (In Russ.).
  15. Calvo C, Fontaine R, Soueid J, et al. Vascular endothelial growth factor receptor 3 directly regulates murine neurogenesis. Genes & Dev. 2011;25:831-844.  https://doi.org/10.1101/gad.615311
  16. Shin YJ, Choi JS, Choi JY, et al. Enhanced expression of vascular endothelial growth factor receptor-3 in the subventricular zone of stroke-lesioned rats. Neurosci Lett. 2010;469(2):194-198.  https://doi.org/10.1016/j.neulet.2009.11.073
  17. Gulevskaya TS, Anufriev PL, Tanashyan MM. Morphology and pathogenesis of white matter changes in chronic cerebrovascular pathology. Annals of Clinical and Experimental Neurology. 2022;16(2):78-88. (In Russ.). https://doi.org/10.54101/ACEN.2022.2.9
  18. Putilina MV. Cognitive disorders in cerebrovascular pathology: a guide for doctors. M.: MAI-Print; 2011. (In Russ.).
  19. Levin OS. Discirculatory encephalopathy: from pathogenesis to treatment. Difficult patient. 2010;8(4):8-15. (In Russ.).
  20. Skoromets AA, Dyakonova MM. Neuroprotection in acute and chronic cerebral circulatory failure. Collection of scientific articles. SPb.: Science; 2007. (In Russ.).
  21. Mashin VV, Belova LA, Chaplanova OI, et al. Open clinical trial of the drug Cortexin for dyscirculatory encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(9):49-52. (In Russ.).
  22. Lutoshkina EB, Salina EA, Sholomov II. Experience in the correction of cognitive impairment with Cortexin and Mexidol in the complex treatment of patients with consequences of cerebral infarction. Neurological Bulletin. 2009;XLI(1):16-19. (In Russ.).
  23. Safronova MN, Kovalenko AV, Mizyurkina OA. Combined neuroprotection in the treatment of post-stroke aphasia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7):20-26. (In Russ.). https://doi.org/10.17116/jnevro201911907120
  24. Piradov MA, Tanashyan MM, Domashenko MA, Maksimova MYu. Neuroprotection in cerebrovascular diseases: the search for life on Mars or a promising direction of treatment? Part 2. Chronic forms of cerebral circulatory disorders. Annals of Neurology. 2015;9(3):10-19. (In Russ.).
  25. Cortexin — five years of experience in domestic neurology. Ed. Skoromtsa A.A., Dyakonova M.M. SPb.: Science; 2005. (In Russ.).
  26. Yanishevsky SN, Tsygan NV, Golokhvastov Syu, et al. Modern protection strategies for hypoxic-ischemic brain damage. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(12):78-86. (In Russ.). https://doi.org/10.17116/jnevro201711712278-86
  27. Abramenko YV. Evaluation of the clinical effectiveness, vasoactive and metabolic effects of Mexidol in elderly patients with dyscirculatory encephalopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(11):35-41. (In Russ.).
  28. Chukanova EI, Chukanova AS, Mamaev HI. Results of the study of effectiveness and safety of Mexidol use in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2015;115(2):71-74. (In Russ.). https://doi.org/10.17116/jnevro20151152171-74
  29. Antipenko EA, Deryugina AV, Gustov AV. Systemic stress-limiting effect of Mexidol in chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(4):28-31. (In Russ.). https://doi.org/10.17116/jnevro20161164128-31
  30. Abramenko YuV. The effect of Mexidol on changes in the lipid-phospholipid profile in acute cerebrovascular accidents in elderly patients. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):68-75. (In Russ.). https://doi.org/10.14412/2074-2711-2018-2-68-75
  31. Voronina TA. The role of oxidative stress and antioxidants in maladaptation of various genesis. Pharmacy and Pharmacology. 2015;3(5):8-17. (In Russ.). https://doi.org/10.19163/2307-9266-2015-3-5s
  32. Voronina TA, Seredenin SB. Guidelines for studying the tranquilizing (anxiolytic) effect of pharmacological substances. Guidelines for experimental (preclinical) study of new pharmacological substances of the Ministry of Health of the Russian Federation. M.: Remedium; 2000. (In Russ.).
  33. Gofman AG, Kozhinova TA, Krylov EN. The use of antioxidants as a means of relieving alcohol withdrawal syndrome. New directions in the creation of medicines. Congress «Man and Medicine». M. 1997;37-39. (In Russ.).
  34. Voronina TA, Kapitsa IG, Ivanova EA. A comparative study of the effect of Mexidol and mildronate on physical performance in an experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(4):70-73. (In Russ.). https://doi.org/10.17116/jnevro20171174171-74
  35. Piradov MA, Tanashyan MM, Domashenko MA, et al. Neuroprotection in cerebrovascular diseases: the search for life on Mars or a promising direction of treatment? Part 1. Acute cerebrovascular accidents. Annals of Clinical and Experimental Neurology. 2015;9(1):41-50. (In Russ.).
  36. Safronova MN, Kovalenko AV, Mizyurkina OA. Combined neuroprotection in the treatment of post-stroke aphasia. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7):20-26. (In Russ.). https://doi.org/10.17116/jnevro201911907120
  37. Mashin VV, Biktimirov TZ, Khramov EV, et al. Neuropsychological diagnostics for lesions of the spinal cord. Scientific notes of Ulyanovsk State University. Ulyanovsk. 1997;36-38. (In Russ.).
  38. Melyokhin AI. Using the clock drawing test in a screening examination of cognitive deficits. Spiritual and Physical Health. National Priorities of Russia. 2014;2(12):186-198. (In Russ.).
  39. Bogolepova AN, Vasenina EE, Gomzyakova NA, et al. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(10-3):6-137. (In Russ.). https://doi.org/10.17116/jnevro20211211036
  40. Steffens DC, Taylor WD, Krishnan KR. Progression of subcortical ischemic disease from vascular depression to vascular dementia. Am J Psychiatry. 2003;160:1751-1756. https://doi.org/10.1176/appi.ajp.160.10.1751
  41. Voznyuk IA, Ponomarev GV, Kharitonova TV, et al. Diagnostic features of the level of antibodies to NR2-peptide in patients with chronic cerebral ischemia. Annals of Clinical and Experimental Neurology. 2021;15(2):5-12. (In Russ.). https://doi.org/10.25692/ACEN.2021.2.1
  42. Davydova EV, Zurochka AV, Altman DSh. Immunobichemical markers of blood-brain barrier permeability and autosensitization in early forms of chronic cerebral ischemia. Russian Immunological Journal. 2018;12(21)3:261-267. (In Russ.). https://doi.org/10.31857/S102872210002392-6
  43. Markelova EV, Zenina AA, Kadyrov RV. Neuropeptides as markers of brain damage. Modern Problems of Science and Education. 2018;5:45-49. (In Russ.).
  44. Blinov DV. Assessment of BBB permeability for neurospecific enolase in perinatal hypoxic-ischemic damage to the central nervous system. Obstetrics, Gynecology and Reproduction. 2013;4:15-19. (In Russ.).
  45. Zhukova AI, Alifirova VM, Zhukova NG. Neurospecific enolase as a specific marker of the neurodegenerative process. Bulletin of Siberian Medicine. 2011;2:15-21. (In Russ.).
  46. Khrapov YuV, Poroisky SV. The role of biomarkers of brain damage in diagnosis, assessment of treatment effectiveness and prediction of outcomes of severe traumatic brain injury. Volgograd Scientific and Medical Journal. 2013;2:10-20. (In Russ.).
  47. Grubb NR, Simpson C, Sherwood RA, et al. Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. Heart. 2007;93:1268-1273. https://doi.org/10.1136/hrt.2006.091314
  48. Anand N, Stead LG. Neuron-specific enolase as a marker for acute ischemic stroke: a systematic review. Cerebrovasc Dis. 2005;20(4):213-219.  https://doi.org/10.1159/000087701
  49. Skoromets AA, Dambinova SA, Dyakonov MM, et al. New biomarkers of brain damages. Neyroimmunologiya. 2009;VII(2):18-23. 
  50. Dambinova SA, Aliev KT, Bondarenko EV, et al. Biomarkers of cerebral ischemia as a new method of proving the effectiveness of neurocytoprotectors. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5):62-67. (In Russ.). https://doi.org/10.17116/jnevro20171175162-67
  51. González-García S, González-Quevedo A, Hernandez-Diaz Z, et al. Circulating autoantibodies against the NR2 peptide of the NMDA receptor are associated with subclinical brain damage in hypertensive patients with other pre-existing conditions for vascular risk. J Neurol Sci. 2017;375:324-330.  https://doi.org/10.1016/j.jns.2017.02.028
  52. Tsygan NV, Trashkov AP. Brain damage and neurotrophic mechanisms of its protection in a model of acute cerebral hypoxia. Bulletin of the Russian Military Medical Academy. 2013;3(43):1-9. (In Russ.).
  53. Emanueli C, Schratzberger P, Kirchmair R, et al. Paracrine control of vascularization and neurogenesis by neurotrophins. Brit J Pharmacol. 2003;140(4):614-619.  https://doi.org/10.1038/sj.bjp.0705458
  54. Lafuente JV, Bulnes S, Mitre B, et al. Role of VEGF in an experimental model of cortical micronecrosis. Aminoacids. 2002;23(1-3):241-245.  https://doi.org/10.1007/s00726-001-0135-1
  55. Rosenstein JM, Mani N, Khaibullina A, et al. Neurotrophic effects of vascular endothelial growth factor on organotypic cortical explants and primary cortical neuron. J Neurosci. 2003;23(35):11036-11044. https://doi.org/10.1523/jneurosci.23-35-11036.2003
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.